128 related articles for article (PubMed ID: 37221820)
1. Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
Kreijne JE; Goetgebuer RL; Erler NS; De Boer NK; Siebers AG; Dijkstra G; van Kemenade FA; Hoentjen F; Oldenburg B; van der Meulen AE; Ponsioen CIJ; Pierik MJ; van der Woude CJ; de Vries AC;
Aliment Pharmacol Ther; 2023 Jul; 58(2):207-217. PubMed ID: 37221820
[TBL] [Abstract][Full Text] [Related]
2. Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.
Goetgebuer RL; Kreijne JE; Aitken CA; Dijkstra G; Hoentjen F; de Boer NK; Oldenburg B; van der Meulen AE; Ponsioen CIJ; Pierik MJ; van Kemenade FJ; de Kok IMCM; Siebers AG; Manniën J; van der Woude CJ; de Vries AC
J Crohns Colitis; 2021 Sep; 15(9):1464-1473. PubMed ID: 33609353
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
5. Risk evaluation for the development of cervical intraepithelial neoplasia: development and validation of risk-scoring schemes.
Lee CH; Peng CY; Li RN; Chen YC; Tsai HT; Hung YH; Chan TF; Huang HL; Lai TC; Wu MT
Int J Cancer; 2015 Jan; 136(2):340-9. PubMed ID: 24841989
[TBL] [Abstract][Full Text] [Related]
6. Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.
Persson M; Elfström KM; Olsson SE; Dillner J; Andersson S
PLoS One; 2015; 10(6):e0127444. PubMed ID: 26083247
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
8. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
9. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.
Schuurman TN; Schaafsma M; To KH; Verhoef VMJ; Sikorska K; Siebers AG; Wenzel HHB; Bleeker MCG; Roes EM; Zweemer RP; de Vos van Steenwijk PJ; Yigit R; Beltman JJ; Zusterzeel PLM; Lok CAR; Bekkers RLM; Mom CH; van Trommel NE
Lancet Oncol; 2023 Dec; 24(12):1349-1358. PubMed ID: 37952541
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
11. Prenatal diethylstilbestrol exposure and high-grade squamous cell neoplasia of the lower genital tract.
Troisi R; Hatch EE; Palmer JR; Titus L; Robboy SJ; Strohsnitter WC; Herbst AL; Adam E; Hyer M; Hoover RN
Am J Obstet Gynecol; 2016 Sep; 215(3):322.e1-8. PubMed ID: 26979629
[TBL] [Abstract][Full Text] [Related]
12. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.
Denny L; Kuhn L; Hu CC; Tsai WY; Wright TC
J Natl Cancer Inst; 2010 Oct; 102(20):1557-67. PubMed ID: 20884893
[TBL] [Abstract][Full Text] [Related]
14. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
15. Long-term observational approach in women with histological diagnosis of cervical low-grade squamous intraepithelial lesion: an Italian multicentric retrospective cohort study.
Ciavattini A; Serri M; Di Giuseppe J; Liverani CA; Gardella B; Papiccio M; Delli Carpini G; Morini S; Clemente N; Sopracordevole F
BMJ Open; 2019 Jul; 9(7):e024920. PubMed ID: 31272971
[TBL] [Abstract][Full Text] [Related]
16. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
17. Role of active and passive smoking in high-risk human papillomavirus infection and cervical intraepithelial neoplasia grade 2 or worse.
Feng RM; Hu SY; Zhao FH; Zhang R; Zhang X; Wallach AI; Qiao YL
J Gynecol Oncol; 2017 Sep; 28(5):e47. PubMed ID: 28657217
[TBL] [Abstract][Full Text] [Related]
18. Extended HPV Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2/3 or Worse in a Cohort Study.
Li X; Rao X; Wei MJ; Lu WG; Xie X; Wang XY
J Natl Compr Canc Netw; 2022 Aug; 20(8):906-914.e10. PubMed ID: 35948040
[TBL] [Abstract][Full Text] [Related]
19. Histopathological profile of cervical punch biopsies and risk factors associated with high-grade cervical precancerous lesions and cancer in northwest Ethiopia.
Derbie A; Amare B; Misgan E; Nibret E; Maier M; Woldeamanuel Y; Abebe T
PLoS One; 2022; 17(9):e0274466. PubMed ID: 36094938
[TBL] [Abstract][Full Text] [Related]
20. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
